A Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211
| Status: | Archived |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2012 |
| Contact: | Ross Vickery, PhD |
| Phone: | 650-808-6000 |
A Phase 1, Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211
This study will examine the effect of an inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A4)
and permeability glycoprotein 1 (P gp) (200 mg itraconazole) on the PK disposition of a 10
mg tablet of TD- 1211 administered orally to fasted subjects.
We found this trial at
1
site
Click here to add this to my saved trials
